靶向Fn14作为恶病质治疗靶点可重编程小鼠肿瘤与脑的糖酵解通路
本研究在小鼠恶病质模型中用[18F]FDG PET/MRI观察糖代谢变化,发现恶病质诱导肿瘤小鼠的肿瘤与脑摄取增高,抗Fn14抗体mAb 002治疗可降低肿瘤摄取(P < 0.05,n = 3),Fn14敲除肿瘤不引起体重下降且不出现摄取随时间增高。
要点
- 恶病质诱导肿瘤小鼠较非恶病质荷瘤小鼠的肿瘤与脑[18F]FDG摄取增高。
- mAb 002治疗可降低肿瘤[18F]FDG摄取(P < 0.05,n = 3)。
- Fn14敲除肿瘤不引起体重下降,也不出现肿瘤与脑摄取随时间增高。
核心结论
- Fn14受体激活与恶病质诱导肿瘤的糖代谢相关联。
研究设计与样本
- 在小鼠恶病质诱导肿瘤模型与不诱导恶病质的模型中进行[18F]FDG PET/MRI成像,并用PMOD软件对PET/MRI融合图像行感兴趣体积分析计算所有肿瘤的SUVaverage。
主要发现
- 恶病质荷瘤小鼠较非恶病质荷瘤小鼠的肿瘤与脑[18F]FDG摄取增高。
- mAb 002治疗可降低肿瘤[18F]FDG摄取(P < 0.05,n = 3)。
- Fn14敲除肿瘤不引起体重下降,且不出现肿瘤与脑[18F]FDG摄取随时间增高。
- 在携带Fn14敲除肿瘤的非恶病质小鼠中,肿瘤[18F]FDG摄取显著低于携带Fn14野生型肿瘤的恶病质小鼠(P < 0.01)。
- 表达Fn14的恶病质诱导肿瘤中,作为糖代谢副产物的l-乳酸生成也增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cachexia is a complex syndrome characterized by unintentional weight loss, progressive muscle wasting and loss of appetite. Anti-Fn14 antibody (mAb 002) targets the TWEAK receptor (Fn14) in murine models of cancer cachexia and can extend the lifespan of mice by restoring the body weight of mice. Here, we investigated glucose metabolic changes in murine models of cachexia via [18F]FDG PET imaging, to explore whether Fn14 plays a role in the metabolic changes that occur during cancer cachexia. METHODS: [18F]FDG PET/MRI imaging was performed in cachexia-inducing tumour models versus models that do not induce cachexia. SUVaverage was calculated for all tumours via volume of interest (VOI) analysis of PET/MRI overlay images using PMOD software. RESULTS: [18F]FDG PET imaging demonstrated increased tumour and brain uptake in cachectic versus non-cachectic tumour-bearing mice. Therapy with mAb 002 was able to reduce [18F]FDG uptake in tumours (P < 0.05, n = 3). Fn14 KO tumours did not induce body weight loss and did not show an increase in [18F]FDG tumour and brain uptake over time. In non-cachectic mice bearing Fn14 KO tumours, [18F]FDG tumour uptake was significantly lower (P < 0.01) than in cachectic mice bearing Fn14 WT counterparts. As a by-product of glucose metabolism, l-lactate production was also increased in cachexia-inducing tumours expressing Fn14. CONCLUSION: Our results demonstrate that Fn14 receptor activation is linked to glucose metabolism of cachexia-inducing tumours.
引用
- Burvenich IJG, Osellame LD, Rigopoulos A, et al. Targeting Fn14 as a therapeutic target for cachexia reprograms the glycolytic pathway in tumour and brain in mice. Eur J Nucl Med Mol Imaging. 2024. PMID: 39060375. doi:10.1007/s00259-024-06836-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。